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Introduction
Progressive supranuclear palsy (PSP) is a neurodegenera-
tive tauopathy, which in the early phases of the disease can 
closely mimic idiopathic Parkinson’s disease (PD). More 
characteristic features including vertical gaze dysfunction 
may only present later, which frequently leads to a delay in 
diagnosis. However, early and accurate diagnosis of PSP is 
of great importance as there are considerable differences in 
disease course, prognosis and management when compared 
to other parkinsonian and non-parkinsonian type neurode-
generative diseases. Furthermore, many of these conditions 
have distinct pathological and prognostic features which will 
guide treatment strategies. Increasingly sophisticated and 
informative neuro-imaging techniques are now becoming 
more widely available and have the considerable advan-
tage of being non-invasive. In this month’s journal club, we 
examine recent evidence supporting the use of imaging in 
diagnosing PSP and other neurodegenerative diseases in a 
series of case–control studies.




This study recruited consecutive patients from a single 
movement disorder clinic to investigate the use of mor-
phological MRI features to differentiate PD from PSP and 
two of its subtypes. It comprised 34 participants with the 
PSP-P (parkinsonism) phenotype, 46 with PSP-RS (Rich-
ardson’s syndrome) and 53 with idiopathic PD and were 
compared with 53 age/sex-matched controls. Participants 
were excluded if imaging detected features of normal pres-
sure hydrocephalus, any vascular lesion, or if they had a 
normal 123I-FP-CIT-SPECT scan. Clinical diagnoses were 
made by a single clinician. Participants underwent Unified 
Parkinsons Disease Rating Scale (UPDRS) motor examina-
tion, mini mental-state examination (MMSE) and Hoehn and 
Yahr staging. Gaze palsy was quantified according to new 
PSP clinical diagnostic criteria as “O1” (significant) or “O2” 
(mid-level).1 All patients underwent a 3T MRI scan at study 
enrolment with automated pons/mid-brain area ratio calcula-
tion, comprising the Magnetic resonance Parkinsons ratio 
(MRPI). Measurements of the third ventricle and frontal 
horn width were added to form a further “MRPI 2.0” index.
MRPI and MRPI 2.0 significantly differentiated between 
PD and PSP (P < 0.001) being higher in PSP. These indi-
ces were also able to differentiate between the PSP-RS and 
PSP-P subtypes (P < 0.001) with indices significantly higher 
in PSP-RS. Accuracies of 88.5% and 96.6% were achieved 
for MRPI and MRPI 2.0, respectively, in differentiating 
PSP-P from PD, and 100% for both indices for PSP-RS 
versus PD. The accuracy of MRPI and MRPI 2.0 values to 
classify patients with PSP-P based on the extent of vertical 
gaze palsy was shown to be 98.5% and 100%, respectively, 
for “O1” grades and 81.9% and 95.8% for “O2” grades.
Comment This paper demonstrates compelling evi-
dence of MRI morphological features to accurately clas-
sify patients to PSP and PD groups, as well as specific PSP 
subgroups. The addition of further morphological features 
to the automated imaging evaluation (MRPI versus MRPI 
2.0) further improved accuracy. The exclusion of individu-
als with vascular lesions on scans may serve to remove the 
population from a comparable clinical cohort and could alter 
the significance of the results. It may also be limited by the 
assumption that the initial clinical diagnosis to which the 
MRI scan is correlated was correct and that there was no 
direct neuropathological confirmation.
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Quattrone et al. (2018) Parkinsonism Relat Disord. 2018 
Sep;54:3–8.
Improved automatic morphology‑based 
classification of Parkinson’s disease 
and progressive supranuclear palsy
In this case comparison study, PSP-RS (n = 22) and PD 
(n = 76) patients were recruited from a single movement 
disorder clinic, to determine whether morphological features 
on MRI combined with clinical features can classify patients 
correctly via a machine learning algorithm. Data were col-
lected on age, gender, disease duration and participants 
underwent UPDRS, MMSE and Hoehn and Yahr assess-
ment. PSP participants with features including freezing and 
levodopa responsiveness were excluded. Participants under-
went 3T T1-weighted scans MRI, parcellated to a brain atlas 
dividing into regions of interest. Surface area and volume 
for each area was calculated and entered into the complex 
machine-learning pipeline with the seven clinical features 
above.
PSP participants were older, with a disease duration of 
half the PD patients. Twenty-one subcortical regions were 
assessed in each group (including brainstem, basal ganglia). 
Volumetric differences in these regions between cohorts 
alone achieved an accuracy of 84.69% in differentiating PSP-
RS versus PD. Adding clinical features increased accuracy 
to 94.89%. Data from regional surface area alone achieved 
85.71% rising to 95.91% with the addition of clinical fea-
tures. A combination of surface area, volumetric features 
and a surface area to volume ratio achieved 88.7% accuracy. 
Adding clinical features to this combination imaging model 
achieved a 97.95% accuracy. A similar analysis adding 48 
cortical regions achieved a similar distribution of accuracies 
with a 97.95% accuracy achieved using all available features.
Comment This study suggests that computer calculated 
morphological features alone can differentiate PSP-RS from 
PD cases with considerable accuracy. The addition of quan-
titative clinical features improves this further. As in the first 
study, the lack of neuropathological confirmation leaves the 
standard to which the machine learning protocol is trained 
and tested dependent on the accuracy of clinical diagnosis. 
Finally, there are considerable differences in age and disease 
duration between the cohorts so that it is difficult to rule 
out an effect of these confounders on the models proposed, 
particularly in terms of regional brain atrophy.
Talai et al. (2018) Clinical Neuroradiology. Sep 14. 
[E-pub ahead of print]
18F‑AV‑1451 positron emission tomography 
in Alzheimer’s disease and progressive 
supranuclear palsy
In another case–control study, the authors have investi-
gated the use of the specific tau binding radioligand 18F-
AV-1451 to differentiate disease in patients with PSP-RS, 
Alzheimer’s disease (AD) and mild cognitive impairment 
(MCI). Participants were recruited from the NIMROD 
(AD, n = 9; MCI, n = 6), and DeNDRoN (PSP, n = 19) 
projects and compared to controls (n = 13). As well as 
demographic data, patients underwent an Addenbrooke’s 
cognitive examination (ACE-R), MMSE and PSP rating 
scale in the PSP cohort specifically. All participants under-
went a 3T MRI scan, and a PET-CT scan with injection of 
the 18F-AV-1451 radioligand. Both scans were partitioned 
into anatomical regions of interest and analysed for 18F-
AV-1451 uptake in specific regions of interest. Variations 
in radioligand uptake were then analysed by a machine 
learning algorithm. A further neuropathological study 
was undertaken on post-mortem single brains from PSP, 
AD or healthy subjects. Brains were divided into sections 
and treated with 18F-AV-1451 prior to phosphor screen 
autoradiography.
Patients were effectively age-matched between groups 
(P = 0.3). Significant regional variations in 18F-AV-1451 
uptake were found (P = 0.00001) based on clinically 
defined group. AD and MCI participants overall had 
higher binding, reflecting the greater burden of tau in 
AD pathology. PSP participants demonstrated increased 
binding in the midbrain (P < 0.04) and pallidum, thalamus, 
putamen and dentate nucleus of the cerebellum (P < 0.02) 
versus AD/MCI groups and controls. AD/MCI groups 
demonstrated increased binding in all cortical structures 
(P < 0.04). 18F-AV-1451 regional binding was correlated 
against ACE-R for all groups and PSP rating scale, with 
no significant difference found suggesting correlation 
between uptake and disease process severity.
The ability of the machine learning algorithm to clas-
sify participants into groups based on scans was then 
assessed. 94.1% accuracy was achieved in differentiating 
AD/MCI versus PSP, 85.7% AD/MCI versus control and 
90.7% PSP versus control. Finally, the paper looked at the 
post-mortem brain sections. Neuropathological studies did 
not show any post-mortem 18F-AV-1451 binding specific 
to PSP.
Comment This study is useful in that it demonstrates 
differences in imaging detectable tau pathology in PSP 
that is discriminatory between controls and an alternative 
common neurodegenerative condition. To further elaborate 
on this work, it would be useful to assess a non tau pathol-
ogy associated parkinsonian disease cohort like a cohort 
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of PD patients as a clinically relevant comparator group 
and observe whether regional binding varied. As per other 
studies, neuropathological evidence is not obtained to con-
firm diagnostic accuracy for PSP in the clinical component 
of the study. However, tying the imaging methodology 
together into the automated machine learning algorithm 
demonstrated good accuracy in discriminating the different 
conditions, suggesting that 18F-AV-1451 maybe a useful 
biomarker for detecting PSP.
Passamonti et al. (2017) Brain. Mar 1;140(3):781–791
Conclusion
These studies each demonstrate evidence that imaging 
modalities such as MRI and tau binding radioligands (F-AV-
1451) can accurately differentiate between PD and PSP dis-
ease states, and even between PSP subtypes. The majority 
of this work has involved quantification of imaging features 
using computerised analysis and, in two cases, machine 
learning algorithms. All studies lacked a neuropathological 
diagnostic confirmation for PSP. The result of this is that 
each study is dependent on the accuracy of the initial asses-
sors recruiting patients to correctly diagnose PSP, which 
acts as the “ground truth” to which the discriminatory abil-
ity of the imaging modalities relies. In common with many 
case–control studies, there are also a range of potential con-
founders that need to taken into consideration. Future work 
to assess the utility of imaging in differentiating PSP from 
other movement disorders such as PD would likely benefit 
from engaging large cohorts with patients at a variety of 
disease stages, carefully matched with control cases and with 
longitudinal neuropathological confirmation at death.
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